NCT05857566View on ClinicalTrials.gov

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

July 13, 2023

Study Completion Date

September 13, 2023

Conditions
Drug-induced Weight Gain
Interventions
DRUG

RDX-002

A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.

Trial Locations (1)

55114

Nucleus Network, Saint Paul

Sponsors
All Listed Sponsors
lead

Response Pharmaceuticals

INDUSTRY

NCT05857566 - Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine | Biotech Hunter | Biotech Hunter